We found that serum NT-pro BNP levels were not significantly different between study groups (63.9±39.8 pg/ml in prolactinoma group, 47.3±31.2 pg/ml in hyperprolactinemia group and 57.2 ± 28.3 pg/ml in control group, p=0.160). Mean cumulative cabergoline dose (CCD) were calculated as 218.1±252.5 (range 52-1248 mg). However, we did not determine any correlations between serum NT-pro BNP levels and cumulative cabergoline dose, and between serum NT-pro BNP and prolactine levels.
Introduction
Cabergoline, a long-lasting dopamine-agonist, is generally considered to be the safety drug for the treatment of prolactinoma. But, use of long time and high dose cabergoline may be a cause of cardiac valvulopathy in patient with prolactinoma. In present study, we aim to determine serum Nterminal probrain natriuretic peptide levels in patients with prolactinoma who were treated with cabergoline.
Method
Thirty patients with prolactinoma who applied to .
